Oregon Psilocybin Services: Demographic Skew Challenges National Policy Extrapolation

Oregon’s Supervised Psilocybin Clients Are Older, Wealthier, and Wellness-Focused

A 2026 cross-sectional study directly compared the demographics and clinical characteristics of individuals accessing Oregon Psilocybin Services (OPS) with those of adults reporting psilocybin use nationally, revealing a marked demographic skew in Oregon’s regulated program. According to the study, which analyzed 5,935 OPS encounters in 2025 and 1,822 past-year psilocybin users from the 2024 National Survey on Drug Use and Health (NSDUH), OPS clients were predominantly female (58.2%) and aged 35 or older (82.1%). In contrast, national psilocybin users skewed male (64.0%) and younger than 35 (56.7%).

Income disparities were pronounced: 58.5% of OPS clients reported earning over $95,000, while the national user base was more economically diverse. Racial and ethnic minority representation was also narrower in Oregon’s program (0.9% Black, 2.5% Hispanic) compared to national figures (5.4% Black, 14.3% Hispanic). Notably, OPS clients primarily cited wellness as their reason for use and had low rates of self-reported disability, while national users reported high rates of psychiatric conditions and substance use disorders.

Mechanisms Behind Oregon’s Demographic Skew

Oregon’s open-access psilocybin model, implemented under Measure 109, was designed to allow adults 21 and older to access supervised psilocybin services without a medical diagnosis. However, the cost of services—often exceeding $1,500 per session—along with geographic concentration of service centers and limited insurance coverage, has created barriers for lower-income and more clinically complex individuals. This has resulted in a clientele that is disproportionately older, wealthier, and focused on personal growth or wellness rather than acute clinical need.

Meanwhile, millions of Americans continue to use psilocybin outside regulated settings, often in unsupervised or underground contexts. The NSDUH data show that these users are more likely to be young, male, racially diverse, and burdened by significant psychiatric and substance use comorbidities. This divergence is not merely a reflection of Oregon’s population but a consequence of the service delivery model’s structure and cost.

Policy and Research Implications: Limits of Generalizability

Policymakers and researchers should be cautious in using Oregon’s safety and utilization data as a proxy for national psilocybin use patterns. The OPS model’s demographic skew means that observed rates of adverse events, utilization patterns, and outcomes may not reflect those of the broader, more clinically burdened population using psilocybin outside supervised channels. For example, the low incidence of self-reported disability and psychiatric comorbidity among OPS clients suggests that findings on safety and efficacy may underestimate risks faced by national users with higher baseline clinical complexity.

This insight challenges a common assumption in policy debates: that data from regulated, open-access models can be directly extrapolated to inform national access, equity, and safety frameworks. Instead, Oregon’s experience highlights the need for targeted outreach, financial support mechanisms, and research designs that capture the diversity of real-world psilocybin use. Notably, the study’s use of both OPS and NSDUH datasets provides a rare, head-to-head comparison, offering policymakers a concrete example of how service design shapes who is reached—and who is left out.

Risks, Unknowns, and Real-World Failure Modes

Generalizing from Oregon’s data risks underestimating both the potential benefits and harms of broader psilocybin access. The current OPS clientele is less likely to have severe psychiatric or substance use disorders, so adverse event rates may be artificially low compared to a more representative population. Conversely, the wellness orientation of OPS clients may lead to overestimation of positive outcomes if applied to individuals with complex clinical histories.

A non-obvious failure mode is that well-intentioned expansion of supervised services—if modeled on Oregon’s fee-for-service structure—could perpetuate inequities and fail to reach those at greatest risk of harm from unsupervised use. This highlights the importance of integrating equity-focused policies, such as sliding-scale fees or public funding, into future regulatory frameworks. Additionally, researchers should prioritize longitudinal studies that track outcomes across diverse populations, including those currently excluded from regulated services.

Looking Ahead: Bridging the Gap Between Regulated and Real-World Use

Future policy and research must explicitly address the mismatch between those reached by supervised psilocybin services and the broader population using these substances. This will require innovative study designs, robust data collection, and deliberate equity interventions to ensure that safety and efficacy findings are relevant to all potential users—not just the affluent and well.

For stakeholders, the Oregon experience offers both a cautionary tale and a roadmap: regulatory models must be evaluated not only for their safety protocols but also for their accessibility and representativeness. As more jurisdictions consider regulated psilocybin services, the challenge will be to design systems that balance safety, access, and equity—grounded in data that truly reflect the populations most at risk and most in need.

Reviewed by Dr. Jamie L. Pearson, PhD (Clinical Psychology). How we research: This article was prepared by reviewing the original OpenAlex study (https://openalex.org/W7211873425), Oregon Health Authority reports, and the 2024 NSDUH public-use file, with all statistics and regulatory details verified against primary sources. Reviewed on 2026-09-08.